You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》安進藥廠下調全年收入預測上限 市後股價偏軟
阿思達克 11-03 11:03
道指成分股,美國安進藥廠(Amgen)(AMGN.US)公佈第三季業績。季度淨利潤18.84億美元,按年跌7%。每股季度純利3.31美元,經調整後爲4.67美元,高於市場預期的4.27美元。季度派息每股1.76美元。期內總收益67.06億美元,按年升4%,符合市場預期。 公司表示,新冠疫情對銷售影響減少,但新處方藥表現在今年仍然呆滯,部分藥物價格仍受低成本競爭對手的壓力。公司下調今年全年收益上限預測4億美元至262億美元,市場預期爲260億美元。全年經調整每股純利由介乎16至17美元,上調至介乎16.5至17.1美元。 安進藥廠股價在延長交易時段跌1.5%,報211美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account